Cardiol Therapeutics (NASDAQ:CRDL) Upgraded at Roth Capital

Roth Capital upgraded shares of Cardiol Therapeutics (NASDAQ:CRDL) to a strong-buy rating in a research note published on Wednesday morning, Zacks.com reports. Roth Capital also issued estimates for Cardiol Therapeutics’ Q2 2024 earnings at ($0.09) EPS, Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS, Q1 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.39) EPS.

A number of other brokerages have also issued reports on CRDL. Roth Mkm started coverage on Cardiol Therapeutics in a research note on Wednesday. They set a buy rating and a $10.00 price target for the company. Canaccord Genuity Group increased their price objective on Cardiol Therapeutics from $6.00 to $8.00 and gave the company a buy rating in a research report on Thursday, May 23rd. Canaccord Genuity Group increased their price objective on Cardiol Therapeutics from $6.00 to $8.00 and gave the company a buy rating in a research report on Thursday, May 23rd. Finally, HC Wainwright reiterated a buy rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a research report on Friday, June 14th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of Buy and a consensus price target of $7.60.

Cardiol Therapeutics Stock Performance

Shares of NASDAQ CRDL opened at $2.02 on Wednesday. The stock has a fifty day moving average price of $2.21 and a two-hundred day moving average price of $1.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.81 and a current ratio of 2.81. The firm has a market cap of $139.38 million, a P/E ratio of -5.77 and a beta of 0.99. Cardiol Therapeutics has a 1 year low of $0.66 and a 1 year high of $3.12.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). Research analysts forecast that Cardiol Therapeutics will post -0.33 EPS for the current fiscal year.

Institutional Trading of Cardiol Therapeutics

An institutional investor recently raised its position in Cardiol Therapeutics stock. Laird Norton Trust Company LLC grew its holdings in Cardiol Therapeutics Inc. (NASDAQ:CRDL) by 63.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,000 shares of the company’s stock after purchasing an additional 38,673 shares during the period. Laird Norton Trust Company LLC owned approximately 0.15% of Cardiol Therapeutics worth $90,000 as of its most recent SEC filing. 12.49% of the stock is currently owned by institutional investors and hedge funds.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.